These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33853586)

  • 1. Comprehensive tumor molecular profile analysis in clinical practice.
    Özdoğan M; Papadopoulou E; Tsoulos N; Tsantikidi A; Mariatou VM; Tsaousis G; Kapeni E; Bourkoula E; Fotiou D; Kapetsis G; Boukovinas I; Touroutoglou N; Fassas A; Adamidis A; Kosmidis P; Trafalis D; Galani E; Lypas G; Orhan B; Tansan S; Özatlı T; Kırca O; Çakır O; Nasioulas G
    BMC Med Genomics; 2021 Apr; 14(1):105. PubMed ID: 33853586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
    Duffy MJ; Crown J
    Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
    Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES
    Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
    Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
    ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients.
    Cao L; Cao Z; Liu H; Liang N; Bing Z; Tian C; Li S
    Curr Oncol; 2022 Aug; 29(8):5715-5730. PubMed ID: 36005189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
    Contos G; Baca Y; Xiu J; Brown J; Holloway R; Korn WM; Herzog TJ; Jones N; Winer I
    Gynecol Oncol; 2021 Nov; 163(2):312-319. PubMed ID: 34563366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
    Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
    Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
    Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
    Front Oncol; 2020; 10():314. PubMed ID: 32232003
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
    Jang BS; Han W; Kim IA
    Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.